Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B

Summary Background Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Methods Data from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were an...

Full description

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 48; no. 3; pp. 300 - 312
Main Authors Han, E., Lee, Y.‐h., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, B.‐W., Kang, E. S., Cha, B.‐S., Han, K.‐H., Kim, S. U.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.08.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Summary Background Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Methods Data from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2]) was calculated using dual‐energy X‐ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut‐offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis‐4 index ≥2.67. Results Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37‐3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67‐3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04‐2.62 by the fibrosis‐4 index; all P < 0.05). Conclusions Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis. Linked ContentThis article is linked to Mudaliar and Liu paper. To view this article visit https://doi.org/10.1111/apt.14894.
AbstractList Linked Content This article is linked to Mudaliar and Liu paper. To view this article visit https://doi.org/10.1111/apt.14894 .
BackgroundSarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B.MethodsData from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2]) was calculated using dual‐energy X‐ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut‐offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis‐4 index ≥2.67.ResultsAmong the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37‐3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67‐3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04‐2.62 by the fibrosis‐4 index; all P < 0.05).ConclusionsSarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.
Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B.BACKGROUNDSarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B.Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2 ]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut-offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index ≥2.67.METHODSData from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2 ]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut-offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index ≥2.67.Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05).RESULTSAmong the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05).Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.CONCLUSIONSSarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.
Summary Background Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Methods Data from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2]) was calculated using dual‐energy X‐ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut‐offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis‐4 index ≥2.67. Results Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37‐3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67‐3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04‐2.62 by the fibrosis‐4 index; all P < 0.05). Conclusions Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis. Linked ContentThis article is linked to Mudaliar and Liu paper. To view this article visit https://doi.org/10.1111/apt.14894.
Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m ]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut-offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index ≥2.67. Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05). Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.
Author Kim, S. U.
Lee, Y.‐h.
Ahn, S. H.
Han, K.‐H.
Han, E.
Park, J. Y.
Lee, B.‐W.
Cha, B.‐S.
Kang, E. S.
Kim, B. K.
Kim, D. Y.
Author_xml – sequence: 1
  givenname: E.
  orcidid: 0000-0002-3237-3317
  surname: Han
  fullname: Han, E.
  organization: Keimyung University School of Medicine
– sequence: 2
  givenname: Y.‐h.
  orcidid: 0000-0002-6219-4942
  surname: Lee
  fullname: Lee, Y.‐h.
  organization: Yonsei University College of Medicine
– sequence: 3
  givenname: B. K.
  surname: Kim
  fullname: Kim, B. K.
  organization: Yonsei University College of Medicine
– sequence: 4
  givenname: J. Y.
  surname: Park
  fullname: Park, J. Y.
  organization: Yonsei University College of Medicine
– sequence: 5
  givenname: D. Y.
  orcidid: 0000-0002-8327-3439
  surname: Kim
  fullname: Kim, D. Y.
  organization: Yonsei University College of Medicine
– sequence: 6
  givenname: S. H.
  surname: Ahn
  fullname: Ahn, S. H.
  organization: Yonsei University College of Medicine
– sequence: 7
  givenname: B.‐W.
  surname: Lee
  fullname: Lee, B.‐W.
  organization: Yonsei University College of Medicine
– sequence: 8
  givenname: E. S.
  surname: Kang
  fullname: Kang, E. S.
  organization: Yonsei University College of Medicine
– sequence: 9
  givenname: B.‐S.
  surname: Cha
  fullname: Cha, B.‐S.
  organization: Yonsei University College of Medicine
– sequence: 10
  givenname: K.‐H.
  surname: Han
  fullname: Han, K.‐H.
  organization: Yonsei University College of Medicine
– sequence: 11
  givenname: S. U.
  orcidid: 0000-0002-9658-8050
  surname: Kim
  fullname: Kim, S. U.
  email: ksukorea@yuhs.ac
  organization: Yonsei University College of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29920701$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAURi1URKeFBS-ALLGBRVr_JE6ybCsKSJVAoqwtx3ND7uCxg-1QzZI3r8tMNxV4Y0s-35F9vxNy5IMHQl5zdsbLOjdzPuN1V8tnZMWlairBpDoiKyZUX4mOy2NyktKGMaZaJl6QY9H3grWMr8ifbybaMINHQzFRk1KwaDKs6R3mieYJaMT0k4aRJvzhcURrfKYOf0OkIw4xpBJDT7eQzRBcuXZuRxc_gXF52tG0DBuwOe19dorBo6UTzCZjLtHLl-T5aFyCV4f9lHy__nB79am6-fLx89XFTWVl18kK-rEe23Lua8bWUkjGm65Rta2NXDcgmehBGeBqkEKYQcmu7iSzkikF0FohT8m7vXeO4dcCKestJgvOGQ9hSVqwpq1rqZgq6Nsn6CYs0ZfXFUp1gnPVPgjfHKhl2MJazxG3Ju7043ALcL4HbJlSijBqi7l8O_gcDTrNmX6oT5f69N_6SuL9k8Sj9F_swX6HDnb_B_XF19t94h5O2KmV
CitedBy_id crossref_primary_10_3350_cmh_2023_0250
crossref_primary_10_1111_jgh_16261
crossref_primary_10_3390_ijms22041917
crossref_primary_10_1002_jcsm_12754
crossref_primary_10_1042_CS20180421
crossref_primary_10_1136_bmjopen_2022_066181
crossref_primary_10_4254_wjh_v14_i8_1652
crossref_primary_10_3390_biomedicines10010182
crossref_primary_10_3390_cancers13143424
crossref_primary_10_1038_s41598_019_48161_w
crossref_primary_10_1080_17474124_2020_1757427
crossref_primary_10_1007_s10620_021_07157_1
crossref_primary_10_1016_j_dld_2020_07_004
crossref_primary_10_1097_MD_0000000000021038
crossref_primary_10_1111_apt_15026
crossref_primary_10_3390_diagnostics13071245
crossref_primary_10_1002_poh2_10
crossref_primary_10_1111_apt_14894
crossref_primary_10_1007_s11901_023_00596_6
crossref_primary_10_3390_life11020086
crossref_primary_10_1097_MEG_0000000000001475
crossref_primary_10_1038_s41598_020_72767_0
crossref_primary_10_1080_19932820_2023_2204564
crossref_primary_10_3892_br_2020_1273
crossref_primary_10_3390_life11040349
crossref_primary_10_5009_gnl220133
crossref_primary_10_1111_apt_17618
crossref_primary_10_5009_gnl19126
crossref_primary_10_1007_s11356_021_16202_5
crossref_primary_10_1186_s12944_021_01472_2
crossref_primary_10_1002_oby_23576
crossref_primary_10_5009_gnl19301
crossref_primary_10_1136_bmjopen_2019_034495
crossref_primary_10_4254_wjh_v15_i5_649
Cites_doi 10.1093/gerona/glu010
10.1053/j.gastro.2008.02.001
10.1093/ije/dyt228
10.1002/lt.22472
10.1016/S0140-6736(12)61425-1
10.1002/hep.21669
10.1161/CIRCULATIONAHA.105.169404
10.1155/2017/2672435
10.1002/hep.28376
10.1210/jc.2013-3764
10.1053/j.gastro.2009.06.005
10.1111/jgh.13536
10.1507/endocrj.EJ17-0225
10.3350/cmh.2014.20.3.228
10.1038/nrgastro.2016.138
10.7326/0003-4819-150-9-200905050-00006
10.1007/s13539-012-0069-3
10.1007/BF00280883
10.4093/jkd.2014.15.2.76
10.1016/j.cgh.2016.05.039
10.1002/hep.21327
10.3851/IMP1982
10.1016/j.jhep.2015.02.051
10.1097/MEG.0000000000000661
10.1016/j.jhep.2016.07.040
10.2147/DDDT.S114761
10.1111/apt.13889
10.1016/j.jhep.2010.02.035
10.3748/wjg.v20.i2.475
10.1007/s13539-011-0035-5
10.1177/0884533612469027
10.1002/hep.23785
10.1136/gut.2008.157735
10.1186/1471-230X-6-33
10.1371/journal.pone.0107584
10.1111/jgh.12432
10.1111/jgh.12998
10.1097/MD.0000000000001682
10.4093/dmj.2011.35.6.561
10.1161/CIR.0b013e3181d0ba8b
10.1111/apt.13549
10.1007/s13539-011-0052-4
10.1053/jhep.2002.36128
10.1016/j.jhep.2016.08.019
ContentType Journal Article
Copyright 2018 John Wiley & Sons Ltd
2018 John Wiley & Sons Ltd.
Copyright © 2018 John Wiley & Sons Ltd
Copyright_xml – notice: 2018 John Wiley & Sons Ltd
– notice: 2018 John Wiley & Sons Ltd.
– notice: Copyright © 2018 John Wiley & Sons Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7U9
H94
K9.
M7N
7X8
DOI 10.1111/apt.14843
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Neurosciences Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitleList CrossRef
AIDS and Cancer Research Abstracts
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2036
EndPage 312
ExternalDocumentID 29920701
10_1111_apt_14843
APT14843
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Republic of Korea
GeographicLocations_xml – name: Republic of Korea
GrantInformation_xml – fundername: Basic Science Research Program
  funderid: 2016R1A1A1A05005138; NRF‐2016R1A5A1010764
– fundername: National Research Foundation of Korea
– fundername: Korea Healthcare Technology R&D Project
  funderid: HI17C0913
– fundername: Research of Korea Centers for Disease Control and Prevention
  funderid: 2016‐ER5103‐00; 2016‐ER5103‐01
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EST
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TR2
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YOC
ZZTAW
~IA
~WT
AAYXX
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7U9
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
H94
K9.
M7N
7X8
ID FETCH-LOGICAL-c3883-e9f4f7c389400d3230158564c4a3d5e3029e6ae16b322ab6384830c3066ee7c23
IEDL.DBID DR2
ISSN 0269-2813
1365-2036
IngestDate Fri Jul 11 11:28:02 EDT 2025
Fri Jul 25 09:48:46 EDT 2025
Wed Feb 19 02:36:54 EST 2025
Thu Apr 24 23:02:21 EDT 2025
Tue Jul 01 02:22:23 EDT 2025
Wed Jan 22 17:05:47 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License 2018 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3883-e9f4f7c389400d3230158564c4a3d5e3029e6ae16b322ab6384830c3066ee7c23
Notes Linked Content
https://doi.org/10.1111/apt.14894
This article is linked to Mudaliar and Liu paper. To view this article visit
.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-3237-3317
0000-0002-9658-8050
0000-0002-8327-3439
0000-0002-6219-4942
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.14843
PMID 29920701
PQID 2068211672
PQPubID 2045200
PageCount 13
ParticipantIDs proquest_miscellaneous_2057443606
proquest_journals_2068211672
pubmed_primary_29920701
crossref_citationtrail_10_1111_apt_14843
crossref_primary_10_1111_apt_14843
wiley_primary_10_1111_apt_14843_APT14843
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2018
2018-08-00
20180801
PublicationDateYYYYMMDD 2018-08-01
PublicationDate_xml – month: 08
  year: 2018
  text: August 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
PublicationTitle Alimentary pharmacology & therapeutics
PublicationTitleAlternate Aliment Pharmacol Ther
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2002; 36
1985; 28
2017; 64
2010; 53
2011; 2
2013; 28
2017; 2017
2005; 112
2015; 94
2017; 66
2015; 30
2017; 45
2010; 121
2016; 10
2016; 32
2014; 69
2006; 6
2009; 150
2011; 35
2012; 18
2015; 13rd edition
2014; 29
2011; 16
2013; 381
2016; 14
2016; 13
2009; 137
2014; 43
2014; 20
2009; 58
2012; 3
2014; 2
2006; 44
2015; 63
2017; 32
2016; 43
2016; 65
2014; 15
2016; 63
2008; 134
2014; 9
2016; 28
2010; 52
2007; 46
2014; 99
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
Wu YJ (e_1_2_7_6_1) 2014; 2
e_1_2_7_19_1
e_1_2_7_18_1
Dasarathy S (e_1_2_7_41_1) 2016; 32
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_10_1
e_1_2_7_46_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_48_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
Hamborsky J KA (e_1_2_7_2_1) 2015
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
e_1_2_7_38_1
e_1_2_7_39_1
30156323 - Aliment Pharmacol Ther. 2018 Sep;48(5):579-580
References_xml – volume: 381
  start-page: 468
  year: 2013
  end-page: 475
  article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study
  publication-title: Lancet
– volume: 66
  start-page: 123
  year: 2017
  end-page: 131
  article-title: Sarcopenia is an independent risk factor for non‐alcoholic steatohepatitis and significant fibrosis
  publication-title: J Hepatol
– volume: 28
  start-page: 412
  year: 1985
  end-page: 419
  article-title: Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man
  publication-title: Diabetologia
– volume: 29
  start-page: 173
  year: 2014
  end-page: 178
  article-title: Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers
  publication-title: J Gastroenterol Hepatol
– volume: 52
  start-page: 886
  year: 2010
  end-page: 893
  article-title: Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
  publication-title: Hepatology
– volume: 28
  start-page: 15
  year: 2013
  end-page: 29
  article-title: Nutrition assessment and management in advanced liver disease
  publication-title: Nutr Clin Pract
– volume: 14
  start-page: 1647
  year: 2016
  end-page: 1656
  article-title: Association between level of fibrosis, rather than antiviral regimen, and outcomes of patients with chronic hepatitis B
  publication-title: Clin Gastroenterol Hepatol
– volume: 3
  start-page: 225
  year: 2012
  end-page: 237
  article-title: Consilience in sarcopenia of cirrhosis
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 10
  start-page: 2739
  year: 2016
  end-page: 2744
  article-title: The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg‐positive chronic hepatitis B and nonalcoholic fatty liver disease
  publication-title: Drug Des Devel Ther
– volume: 69
  start-page: 547
  year: 2014
  end-page: 558
  article-title: The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates
  publication-title: J Gerontol A Biol Sci Med Sci
– volume: 15
  start-page: 76
  year: 2014
  end-page: 81
  article-title: Causal relationship of non‐alcoholic fatty liver disease with obesity and insulin resistance
  publication-title: J Korean Diabetes
– volume: 63
  start-page: 486
  year: 2015
  end-page: 493
  article-title: Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008‐2011)
  publication-title: J Hepatol
– volume: 2
  start-page: 143
  year: 2011
  end-page: 151
  article-title: The role of myostatin in muscle wasting: an overview
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 137
  start-page: 865
  year: 2009
  end-page: 872
  article-title: Prediction of non‐alcoholic fatty liver disease and liver fat using metabolic and genetic factors
  publication-title: Gastroenterology
– volume: 3
  start-page: 77
  year: 2012
  end-page: 94
  article-title: Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 43
  start-page: 765
  year: 2016
  end-page: 777
  article-title: Review article: sarcopenia in cirrhosis–aetiology, implications and potential therapeutic interventions
  publication-title: Aliment Pharmacol Ther
– volume: 46
  start-page: 32
  year: 2007
  end-page: 36
  article-title: FIB‐4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest
  publication-title: Hepatology
– volume: 53
  start-page: 348
  year: 2010
  end-page: 356
  article-title: Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review
  publication-title: J Hepatol
– volume: 35
  start-page: 561
  year: 2011
  end-page: 566
  article-title: Obesity and metabolic syndrome in Korea
  publication-title: Diabetes Metab J
– volume: 2
  start-page: 222
  year: 2014
  end-page: 227
  article-title: Clinical advances in fibrosis progression of chronic hepatitis B and C
  publication-title: J Clin Transl Hepatol
– volume: 44
  start-page: 865
  year: 2006
  end-page: 873
  article-title: Long‐term follow‐up of patients with NAFLD and elevated liver enzymes
  publication-title: Hepatology
– volume: 13rd edition
  year: 2015
– volume: 58
  start-page: 111
  year: 2009
  end-page: 117
  article-title: Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B
  publication-title: Gut
– volume: 150
  start-page: 604
  year: 2009
  end-page: 612
  article-title: A new equation to estimate glomerular filtration rate
  publication-title: Ann Intern Med
– volume: 20
  start-page: 228
  year: 2014
  end-page: 236
  article-title: Prediction of fibrosis progression in chronic viral hepatitis
  publication-title: Clin Mol Hepatol
– volume: 13
  start-page: 643
  year: 2016
  end-page: 653
  article-title: Screening and diagnosis of HBV in low‐income and middle‐income countries
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 9
  start-page: e107584
  year: 2014
  article-title: Non‐laboratory‐based self‐assessment screening score for non‐alcoholic fatty liver disease: development, validation and comparison with other scores
  publication-title: PLoS ONE
– volume: 43
  start-page: 69
  year: 2014
  end-page: 77
  article-title: Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES)
  publication-title: Int J Epidemiol
– volume: 28
  start-page: 940
  year: 2016
  end-page: 947
  article-title: Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease
  publication-title: Eur J Gastroenterol Hepatol
– volume: 134
  start-page: 1729
  year: 2008
  end-page: 1740
  article-title: Nutrition in end‐stage liver disease: principles and practice
  publication-title: Gastroenterology
– volume: 65
  start-page: 1232
  year: 2016
  end-page: 1244
  article-title: Sarcopenia from mechanism to diagnosis and treatment in liver disease
  publication-title: J Hepatol
– volume: 45
  start-page: 510
  year: 2017
  end-page: 518
  article-title: Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease
  publication-title: Aliment Pharmacol Ther
– volume: 30
  start-page: 1753
  year: 2015
  end-page: 1758
  article-title: Thyroid function is associated with non‐alcoholic fatty liver disease in chronic hepatitis B‐infected subjects
  publication-title: J Gastroenterol Hepatol
– volume: 6
  start-page: 33
  year: 2006
  article-title: The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
  publication-title: BMC Gastroenterol
– volume: 2017
  start-page: 2672435
  year: 2017
  article-title: Exercise and protein intake: a synergistic approach against Sarcopenia
  publication-title: Biomed Res Int
– volume: 36
  start-page: 986
  year: 2002
  end-page: 992
  article-title: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
  publication-title: Hepatology
– volume: 121
  start-page: 354
  year: 2010
  end-page: 356
  article-title: Myostatin: regulator of muscle wasting in heart failure and treatment target for cardiac cachexia
  publication-title: Circulation
– volume: 63
  start-page: 776
  year: 2016
  end-page: 786
  article-title: Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011)
  publication-title: Hepatology
– volume: 94
  start-page: e1682
  year: 2015
  article-title: Validation of the fatty liver index for nonalcoholic fatty liver disease in middle‐aged and elderly Chinese
  publication-title: Medicine (Baltimore)
– volume: 32
  start-page: 159
  year: 2016
  end-page: 165
  article-title: Cause and management of muscle wasting in chronic liver disease
  publication-title: Curr Opin Gastroenterol
– volume: 64
  start-page: 1137
  year: 2017
  end-page: 1142
  article-title: Free testosterone concentration is inversely associated with markers of liver fibrosis in men with type 2 diabetes mellitus
  publication-title: Endocr J
– volume: 99
  start-page: 3879
  year: 2014
  end-page: 3888
  article-title: The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture: results from the KNHANES 2008‐2011
  publication-title: J Clin Endocrinol Metab
– volume: 112
  start-page: 2735
  year: 2005
  end-page: 2752
  article-title: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
  publication-title: Circulation
– volume: 32
  start-page: 667
  year: 2017
  end-page: 676
  article-title: Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B
  publication-title: J Gastroenterol Hepatol
– volume: 16
  start-page: 1169
  year: 2011
  end-page: 1186
  article-title: HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B
  publication-title: Antivir Ther
– volume: 20
  start-page: 475
  year: 2014
  end-page: 485
  article-title: Limitations of liver biopsy and non‐invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
  publication-title: World J Gastroenterol
– volume: 18
  start-page: 146
  year: 2012
  end-page: 151
  article-title: Exercise capacity and muscle strength in patients with cirrhosis
  publication-title: Liver Transpl
– ident: e_1_2_7_17_1
  doi: 10.1093/gerona/glu010
– ident: e_1_2_7_10_1
  doi: 10.1053/j.gastro.2008.02.001
– ident: e_1_2_7_16_1
  doi: 10.1093/ije/dyt228
– ident: e_1_2_7_42_1
  doi: 10.1002/lt.22472
– volume: 2
  start-page: 222
  year: 2014
  ident: e_1_2_7_6_1
  article-title: Clinical advances in fibrosis progression of chronic hepatitis B and C
  publication-title: J Clin Transl Hepatol
– ident: e_1_2_7_7_1
  doi: 10.1016/S0140-6736(12)61425-1
– ident: e_1_2_7_21_1
  doi: 10.1002/hep.21669
– ident: e_1_2_7_29_1
  doi: 10.1161/CIRCULATIONAHA.105.169404
– ident: e_1_2_7_30_1
  doi: 10.1155/2017/2672435
– ident: e_1_2_7_14_1
  doi: 10.1002/hep.28376
– ident: e_1_2_7_18_1
  doi: 10.1210/jc.2013-3764
– ident: e_1_2_7_20_1
  doi: 10.1053/j.gastro.2009.06.005
– ident: e_1_2_7_35_1
  doi: 10.1111/jgh.13536
– volume: 32
  start-page: 159
  year: 2016
  ident: e_1_2_7_41_1
  article-title: Cause and management of muscle wasting in chronic liver disease
  publication-title: Curr Opin Gastroenterol
– ident: e_1_2_7_47_1
  doi: 10.1507/endocrj.EJ17-0225
– ident: e_1_2_7_5_1
  doi: 10.3350/cmh.2014.20.3.228
– ident: e_1_2_7_3_1
  doi: 10.1038/nrgastro.2016.138
– volume-title: Epidemiology and Prevention of Vaccine‐Preventable Diseases
  year: 2015
  ident: e_1_2_7_2_1
– ident: e_1_2_7_19_1
  doi: 10.7326/0003-4819-150-9-200905050-00006
– ident: e_1_2_7_9_1
  doi: 10.1007/s13539-012-0069-3
– ident: e_1_2_7_28_1
  doi: 10.1007/BF00280883
– ident: e_1_2_7_38_1
  doi: 10.4093/jkd.2014.15.2.76
– ident: e_1_2_7_32_1
  doi: 10.1016/j.cgh.2016.05.039
– ident: e_1_2_7_33_1
  doi: 10.1002/hep.21327
– ident: e_1_2_7_4_1
  doi: 10.3851/IMP1982
– ident: e_1_2_7_13_1
  doi: 10.1016/j.jhep.2015.02.051
– ident: e_1_2_7_31_1
  doi: 10.1097/MEG.0000000000000661
– ident: e_1_2_7_43_1
  doi: 10.1016/j.jhep.2016.07.040
– ident: e_1_2_7_39_1
  doi: 10.2147/DDDT.S114761
– ident: e_1_2_7_45_1
  doi: 10.1111/apt.13889
– ident: e_1_2_7_34_1
  doi: 10.1016/j.jhep.2010.02.035
– ident: e_1_2_7_26_1
  doi: 10.3748/wjg.v20.i2.475
– ident: e_1_2_7_11_1
  doi: 10.1007/s13539-011-0035-5
– ident: e_1_2_7_48_1
  doi: 10.1177/0884533612469027
– ident: e_1_2_7_8_1
  doi: 10.1002/hep.23785
– ident: e_1_2_7_36_1
  doi: 10.1136/gut.2008.157735
– ident: e_1_2_7_24_1
  doi: 10.1186/1471-230X-6-33
– ident: e_1_2_7_25_1
  doi: 10.1371/journal.pone.0107584
– ident: e_1_2_7_44_1
  doi: 10.1111/jgh.12432
– ident: e_1_2_7_46_1
  doi: 10.1111/jgh.12998
– ident: e_1_2_7_23_1
  doi: 10.1097/MD.0000000000001682
– ident: e_1_2_7_27_1
  doi: 10.4093/dmj.2011.35.6.561
– ident: e_1_2_7_12_1
  doi: 10.1161/CIR.0b013e3181d0ba8b
– ident: e_1_2_7_37_1
  doi: 10.1111/apt.13549
– ident: e_1_2_7_40_1
  doi: 10.1007/s13539-011-0052-4
– ident: e_1_2_7_22_1
  doi: 10.1053/jhep.2002.36128
– ident: e_1_2_7_15_1
  doi: 10.1016/j.jhep.2016.08.019
– reference: 30156323 - Aliment Pharmacol Ther. 2018 Sep;48(5):579-580
SSID ssj0006702
Score 2.420683
Snippet Summary Background Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver...
Linked Content This article is linked to Mudaliar and Liu paper. To view this article visit https://doi.org/10.1111/apt.14894 .
Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals...
BackgroundSarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 300
SubjectTerms Absorptiometry, Photon
Adult
Aged
Body Mass Index
Cross-Sectional Studies
Fatty liver
Female
Fibrosis
Hepatitis
Hepatitis B
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - epidemiology
Humans
Insulin
Insulin Resistance
Liver Cirrhosis - complications
Liver Cirrhosis - epidemiology
Liver diseases
Male
Metabolic Diseases - complications
Metabolic Diseases - epidemiology
Metabolic syndrome
Metabolic Syndrome - complications
Metabolic Syndrome - epidemiology
Middle Aged
Non-alcoholic Fatty Liver Disease - complications
Non-alcoholic Fatty Liver Disease - epidemiology
Nutrition Surveys
Obesity
Obesity - complications
Obesity - epidemiology
Population studies
Republic of Korea - epidemiology
Risk Factors
Sarcopenia
Sarcopenia - complications
Sarcopenia - diagnosis
Sarcopenia - epidemiology
Skeletal muscle
Steatosis
Title Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.14843
https://www.ncbi.nlm.nih.gov/pubmed/29920701
https://www.proquest.com/docview/2068211672
https://www.proquest.com/docview/2057443606
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEB9EQe5FvQ91PU_i4cO9VNImzab4tHt3iwiK-AE-HJS0m-Li2hXbPujb_efONG3VU-HwLdCkTTPzy8wkv0wAdjIusyhMAg-tW-hJnXGcByPj2TA0WuiQW8e2OFL75_LgIryYg732LIzLD9EtuBEy6vmaAG6S4gnIzU2JMNeSMn0SV4scopPH1FGqX_MNMcSIvED7oskqRCyeruVzW_TCwXzur9YGZ7QMf9quOp7J1W5VJrvp_T9ZHN_5Lyuw1DiibOA05yPM2fwTLB42W-2f4e8pQoDu1poYNimYacRox4yWbhn6jYxo6WyWMeKAEOMIhcSmxPNgGfZmVmCzSc6ubYmKRmuD0-kdq3J38vKOFVVCa0CFe1_qkvSyS0sU7xKbDr_A-ej32c99r7mvwUuF1sKzUSazPpbpsvWxwODGRwVQMpVGjEMreBBZZayvEpxFTILIl1rwFIMWZW0_DcQqzOez3K4D09JHz0Ja1J1IKm60HBuj0JIqjtE8z3rwo5VcnDbJzOlOjWncBjU4pHE9pD343lW9cRk8Xqu02Yo_bkBcxAFXOqB9qqAH291jhB_tqZjcziqqE_alFBgG9mDNqU33FbT0AXbWx87Wwn_78_Hg-KwubPx_1a_wAZ037ciImzBf3lb2GzpIZbIFC4Phr-Foq0bEA58oDCw
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkAqXlvLclrYu6oFLkBM7XkfiQlvQtgVUwSJxQZGTdcSKJYua5EBv_PPOxEkoFKSqt0hrb5zMfJ6Hv8wAfMy4zKIwCTy0bqEndcZxH4yMZ8PQaKFDbh3b4kgNTuW3s_BsBnbab2FcfYgu4UbIqPdrAjglpP9AubkuEedaimcwRx29qXL-l-O74lGqXzMOMciIvED7oqkrRDyebup9a_SXi3nfY61Nzv5LOG8X65gml9tVmWynvx7Ucfzfp1mEF40vynad8ryCGZsvwfPD5rR9GW5PEAXUXmts2LhgppGkHTHK3jJ0HRkx09k0Y0QDIdIRyolNiOrBMlzOtMBp45xd2RJ1jdKDk8kNq3L38eUNK6qE0kCF-7_U1ellF5ZY3iVO_bQCp_t7w88Dr2nZ4KVCa-HZKJNZH6-p3_pIYHzjow4omUojRqEVPIisMtZXCW4kJkHwSy14inGLsrafBmIVZvNpbteBaemjcyEtqk8kFTdajoxRaEwVx4CeZz3YakUXp009c2qrMYnbuAZfaVy_0h5sdkOvXRGPxwZttPKPGxwXccCVDuioKujBh-5nRCAdq5jcTisaE_alFBgJ9mDN6U13FzT2AS7Wx8XW0n_69vHuj2F98frfh76H-cHw8CA--Hr0_Q0soC-nHTdxA2bLn5V9i_5SmbyrYfEb45AO1g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9VAEJ4AJoSLoCg-RFmNBy4lbXe73YYTii-ASgg_Eg4mzbbdjS8--15se8Cb_7kz3baKSkK4Neluu92Zb2dm9-sMwBvrC5tEWeihdYs8oayP62CiPRNFWnEV-caxLU7k4aU4voquFmCv_xfG5YcYNtwIGe16TQCfF_YPkOt5jTBXgi_CAyH9hOo2HJz9zh0l45ZwiDFG4oUq4F1aIaLxDF1vGqN_PMybDmtrccar8LkfqyOafN1t6mw3__FXGsd7fswaPOw8UbbvVOcRLJjyMSx_6s7a1-HnOWKAimtNNJtUTHdyNAWjvVuGjiMjXjqbWUYkEKIcoZTYlIgezOJoZhV2m5Tsm6lR02hzcDq9Zk3pfr28ZlWT0SZQ5Z6Xuyy97IshjneNXd8-gcvx-4t3h15XsMHLuVLcM4kVNsZrqrZecIxuAtQAKXKheREZ7oeJkdoEMsNlRGcIfaG4n2PUIo2J85A_haVyVppnwJQI0LUQBpUnQelqJQqtJZpSknTs2xHs9JJL8y6bORXVmKZ9VINTmrZTOoLXQ9O5S-Hxv0ZbvfjTDsVVGvpShXRQFY7g1XAb8UeHKro0s4baRLEQHOPAEWw4tRnegqY-xMEGONhW-Le_Pt0_vWgvNu_edBuWTw_G6cejkw_PYQUdOeWIiVuwVH9vzAt0lursZQuKX64hDYU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sarcopenia+is+associated+with+the+risk+of+significant+liver+fibrosis+in+metabolically+unhealthy+subjects+with+chronic+hepatitis+B&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Han%2C+E&rft.au=Lee%2C+Y-H&rft.au=Kim%2C+B+K&rft.au=Park%2C+J+Y&rft.date=2018-08-01&rft.eissn=1365-2036&rft.volume=48&rft.issue=3&rft.spage=300&rft_id=info:doi/10.1111%2Fapt.14843&rft_id=info%3Apmid%2F29920701&rft.externalDocID=29920701
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon